BRIAN GILBERT to Antiviral Agents
This is a "connection" page, showing publications BRIAN GILBERT has written about Antiviral Agents.
Connection Strength
0.701
-
MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res. 2008 Jun; 78(3):223-9.
Score: 0.181
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
Score: 0.095
-
GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1264-73.
Score: 0.078
-
Benzimidazole analogs inhibit respiratory syncytial virus G protein function. Antiviral Res. 2015 Sep; 121:31-8.
Score: 0.075
-
Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26; 58(4):1630-43.
Score: 0.073
-
Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One. 2012; 7(1):e30596.
Score: 0.059
-
Augmented lung inflammation protects against influenza A pneumonia. PLoS One. 2009; 4(1):e4176.
Score: 0.048
-
Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005 Oct; 68(1):18-26.
Score: 0.038
-
Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003 Nov; 60(3):221-31.
Score: 0.034
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
Score: 0.019